Autolus Therapeutics (AUTL) director discloses long-dated ADS option grants

Rhea-AI Filing Summary

Autolus Therapeutics plc director William D. Young has reported his derivative holdings in a Form 3 filing, showing options over American Depositary Shares. The disclosure lists several share option awards with exercise prices between $2.32 and $5.56 per ADS and expirations from November 2031 through June 2035. The filing notes that some options are fully vested and exercisable, while another grant vests in twelve equal monthly installments commencing on July 26, 2025. No purchases or sales of shares are reported; this filing establishes his initial reported ownership position in option awards.

Insights

Insider transactions analyst

Form 3 lists existing option grants with no new trades.

This Form 3 for Autolus Therapeutics plc records director William D. Young’s existing share option awards over American Depositary Shares. Exercise prices range from $2.32 to $5.56, with expirations stretching from 2031 to 2035, indicating a long-dated equity incentive structure.

The footnotes state that at least one option grant is fully vested and exercisable, and another vests in twelve equal monthly installments starting on July 26, 2025. Because the transaction summary shows no buys, sells, exercises, or gifts, this filing is administrative rather than a trading signal.

For investors, the key takeaway is that a board member holds multiple option packages aligned with long-term company performance. Subsequent Forms 4, if any, would show future exercises or sales and provide more direct insight into his trading activity.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

YOUNG WILLIAM D

(Last) (First) (Middle)

C/O AUTOLUS THERAPEUTICS PLC

THE MEDIAWORKS, 191 WOOD LN, WHITE CITY

(Street)

LONDON W12 7FP

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Autolus Therapeutics plc [ AUTL ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (right to buy)	(1)	11/06/2031	American Depositary Shares	25,000	$5.56	D
Share Option (right to buy)	(1)	06/28/2032	American Depositary Shares	20,000	$2.84	D
Share Option (right to buy)	(1)	06/30/2033	American Depositary Shares	105,000	$2.38	D
Share Option (right to buy)	(1)	06/28/2034	American Depositary Shares	80,000	$3.48	D
Share Option (right to buy)	(2)	06/26/2035	American Depositary Shares	80,000	$2.32	D

Explanation of Responses:

1. Fully vested and exercisable.

2. This option vested or vests in twelve equal monthly installments commencing on July 26, 2025.

	/s/ William Young	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Autolus Therapeutics (AUTL) Form 3 for William D. Young report?

The Form 3 reports director William D. Young’s existing share option awards over Autolus Therapeutics American Depositary Shares. It lists multiple option grants with specific exercise prices, expiration dates, and vesting terms, but does not show any purchases or sales of shares.

What option grants over ADSs does William D. Young hold in AUTL?

William D. Young holds several share options over Autolus Therapeutics American Depositary Shares with exercise prices between $2.32 and $5.56 per ADS. These options have expiration dates ranging from November 2031 through June 2035, reflecting long-term equity incentives tied to the company’s performance.

Are any of William D. Young’s Autolus Therapeutics options vested?

Yes. A footnote states that at least one of William D. Young’s option grants is fully vested and exercisable. Another option is scheduled to vest in twelve equal monthly installments commencing on July 26, 2025, gradually increasing his exercisable position over time.

Does the AUTL Form 3 show any insider buying or selling by William D. Young?

No. The Form 3 for Autolus Therapeutics shows only derivative holdings and classifies all entries as holdings with unknown transaction codes. The transaction summary indicates no buys, sells, exercises, gifts, or tax-withholding events, so it provides no insider trading signal.

What does the vesting schedule in the Autolus Therapeutics Form 3 indicate?

The filing states that one option grant vests in twelve equal monthly installments starting July 26, 2025. This means the award becomes exercisable gradually over a one-year period, aligning William D. Young’s compensation with sustained service and Autolus Therapeutics’ longer-term performance.